1. Introduction

Deep-Sea Organism Patent Conflicts refer to legal disputes concerning the ownership, patentability, commercial exploitation, and intellectual property protection of biological organisms, genetic materials, enzymes, microorganisms, and other biological resources discovered in the deep ocean.

Deep-sea environments contain extraordinary biological diversity. Organisms living near hydrothermal vents, cold seeps, underwater mountains, and deep-sea trenches often possess unusual biological characteristics that enable them to survive extreme pressure, darkness, low temperatures, and high concentrations of minerals.

These organisms may provide commercially valuable discoveries, including:

Heat-resistant and pressure-resistant enzymes.

Novel antibiotics and pharmaceutical compounds.

Marine microorganisms useful in biotechnology.

Genetic materials for industrial applications.

Organisms potentially useful in cancer research.

Biological compounds for cosmetics and agriculture.

The central legal controversy is whether a private company or researcher can obtain exclusive patent rights over inventions derived from organisms collected from international waters, even though those biological resources may constitute part of the shared natural heritage of humanity.

The conflict involves patent law, international maritime law, biodiversity conservation, biotechnology regulation, scientific research, and equitable benefit-sharing.

The fundamental legal distinction: Discovering a naturally occurring deep-sea organism does not automatically create a patentable invention. However, a genuinely inventive and sufficiently disclosed technological application derived from that organism may qualify for patent protection, depending on the applicable national law.

2. Major Legal Issues in Deep-Sea Organism Patent Conflicts

A. Patentability of Naturally Occurring Deep-Sea Organisms

The first major issue is whether a naturally existing marine organism can be patented.

For example, a researcher discovers a microorganism near a hydrothermal vent that produces an enzyme capable of surviving extremely high temperatures.

The researcher may attempt to patent:

The naturally occurring microorganism.

Its isolated genetic sequence.

A modified version of the microorganism.

A genetically engineered enzyme.

A novel industrial process using the enzyme.

A pharmaceutical composition containing a derived compound.

These claims must be examined separately.

A naturally occurring organism or biological characteristic is generally not patentable merely because it has been discovered for the first time. However, an artificially modified microorganism, a novel engineered composition, or a genuinely inventive application may be patentable.

Important case laws

1. Diamond v. Chakrabarty (1980), 447 U.S. 303

The US Supreme Court considered whether a genetically engineered bacterium capable of breaking down crude oil could receive patent protection.

The Court held that a human-made microorganism with characteristics significantly different from naturally occurring organisms could constitute patentable subject matter.

Legal principle: A genetically engineered deep-sea microorganism may qualify for patent protection if it represents a human-made invention rather than merely a discovery of nature.

LII / Legal Information Institute+1

2. Funk Brothers Seed Co. v. Kalo Inoculant Co. (1948), 333 U.S. 127

The US Supreme Court rejected patent protection for a mixture of naturally occurring bacterial species because the bacteria retained their existing natural characteristics and functions.

Legal principle: Merely collecting, combining, or identifying naturally occurring microorganisms does not necessarily constitute an inventive contribution.

LII / Legal Information Institute

B. Ownership of Genetic Resources Collected from International Waters

A major controversy arises when researchers collect biological samples from areas beyond national jurisdiction.

The questions include:

Who owns the collected organism?

Can a private corporation claim exclusive commercial rights?

Can another country conduct independent research on the same organism?

Must commercial users share benefits with the international community?

Does the patent holder acquire ownership over the original marine organism?

Patent ownership and ownership of the biological sample are legally distinct. A patent does not automatically grant sovereignty over the ocean, ownership of an entire species, or unrestricted control over all naturally occurring specimens.

The United Nations Convention on the Law of the Sea (UNCLOS) establishes an important distinction between marine genetic resources found in national maritime zones and resources associated with the international seabed Area.

The international seabed Area and its mineral resources are governed by a special common-heritage regime. However, the legal treatment of marine genetic resources has historically involved interpretative disagreements.

The 2023 BBNJ Agreement addresses marine genetic resources, including benefit-sharing, in areas beyond national jurisdiction. It entered into force on 17 January 2026.

This creates an important legal framework for regulating access, research, information-sharing, and commercial benefits arising from marine genetic resources.

C. Biopiracy and Unauthorised Commercial Exploitation

Biopiracy occurs when biological resources or associated traditional knowledge are commercially exploited without appropriate authorisation, recognition, or benefit-sharing.

In deep-sea biotechnology, this problem may arise when a corporation:

Collects microorganisms from international waters.

Identifies commercially useful genetic sequences.

Develops a pharmaceutical or industrial product.

Files patents in several countries.

Commercialises the invention without adequately addressing applicable benefit-sharing obligations.

The legal difficulty is determining which international benefit-sharing rules apply, particularly where the organism was collected before a treaty entered into force or where its geographical origin is uncertain.

The Nagoya Protocol primarily concerns genetic resources within the scope of the Convention on Biological Diversity. It should not automatically be treated as the governing benefit-sharing instrument for marine genetic resources from areas beyond national jurisdiction.

The BBNJ Agreement provides a specific international framework for the latter category.

3. Important Judicial Decisions and Patent Disputes

D. Genetic Sequence and Marine DNA Patent Conflicts

A particularly difficult question concerns whether companies can patent genetic sequences obtained from deep-sea microorganisms.

Suppose a pharmaceutical company identifies a gene responsible for producing a new antibiotic in a deep-sea bacterium. It isolates the gene and files a patent application.

Another research institution may argue that the genetic sequence already exists in nature and cannot be privately appropriated.

3. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013), 569 U.S. 576

The US Supreme Court examined patents involving the BRCA1 and BRCA2 genes.

The Court held that naturally occurring DNA sequences are not patentable merely because they have been isolated. However, synthetically created complementary DNA (cDNA) may be patentable because it is not naturally occurring.

Application to deep-sea organisms: A company cannot assume that discovering and isolating a naturally occurring marine gene automatically creates patent rights. However, a sufficiently inventive synthetic genetic construct or technological application may qualify.

Justia U.S. Supreme Court Center+1

E. International Biotechnology Patent Protection

4. Kingdom of the Netherlands v. European Parliament and Council (2001), Case C-377/98

The European Court of Justice considered the validity of Directive 98/44/EC on the legal protection of biotechnological inventions.

The Netherlands challenged the Directive on several grounds, including legal certainty, ethical concerns, and the patentability of biological material.

The Court rejected the challenge and upheld the Directive.

An important distinction recognised in the Directive is that a naturally existing biological element cannot simply be appropriated, whereas biological material isolated through a technical process may qualify for patent protection when the statutory requirements are satisfied, including an identified industrial application.

Application: A deep-sea microorganism may be relevant to a patent application when it has been technically isolated and its claimed industrial application satisfies the applicable patentability standards.

EUR-Lex+1

F. Patent Rights and the Scope of Genetic Material Protection

5. Monsanto Technology LLC v. Cefetra BV (2010), Case C-428/08

This case concerned Monsanto's patented genetic material in genetically modified soybeans imported into Europe.

The dispute involved whether patent protection extended to genetic material present in soybean meal when that genetic material no longer performed its patented biological function.

The European Court of Justice held that the protection under Article 9 of the Biotechnology Directive did not apply where the genetic information was present in the material but no longer performed the function for which it had been patented.

Application: A company holding a patent over a particular marine genetic sequence cannot necessarily claim control over every product containing that sequence. The actual patent claims and the applicable legal requirements determine the scope of protection.

epo.org+1

G. Commercial Patent Conflicts Involving Marine Microorganisms

6. Butamax Advanced Biofuels v. Gevo – Marine Archaea and Biofuel Patent Disputes

An important real-world example concerns the marine archaeal species Methanococcus maripaludis.

Research identified an enzyme from this microorganism that played a role in the production of isobutanol.

Butamax and Gevo became involved in a series of patent disputes concerning technologies for producing isobutanol using microorganisms.

The disputes were eventually resolved through licensing arrangements, and Gevo subsequently acquired Butamax's patents in 2021.

This example illustrates how biological sequences and enzymes originating from marine microorganisms can become commercially valuable intellectual property.

Legal significance: Patent disputes involving marine genetic material may concern ownership of particular technological applications, enzyme systems, engineered microorganisms, and licensing rights rather than ownership of the naturally occurring species itself.

Importantly, this was a commercial patent dispute, not a judicial ruling establishing ownership rights over deep-sea organisms.

Nature Sustainability

4. UNCLOS and the Common Heritage of Humankind

The United Nations Convention on the Law of the Sea (UNCLOS) is an important international legal instrument for resolving disputes involving deep-sea resources.

Article 136: Common Heritage of Humankind

Article 136 declares that the international seabed Area and its resources constitute the common heritage of humankind.

Article 137: Legal Status of the Area and Its Resources

Article 137 prohibits States and private persons from claiming sovereignty or appropriating the Area and its resources contrary to the Convention.

However, an important legal distinction must be maintained.

The UNCLOS common-heritage regime expressly addresses the Area and its resources, while its application to marine genetic resources has historically raised interpretative questions.

The BBNJ Agreement now establishes a dedicated framework for marine genetic resources in areas beyond national jurisdiction.

Part XI, Section 2+1

The BBNJ Agreement, 2023

The BBNJ Agreement entered into force on 17 January 2026.

It establishes international rules concerning:

Access to marine genetic resources in areas beyond national jurisdiction.

Fair and equitable sharing of benefits.

Scientific research and international cooperation.

Capacity-building and technology transfer.

Digital sequence information associated with marine genetic resources.

Conservation and sustainable use of marine biodiversity.

The Agreement is particularly significant because marine genetic resources may generate both monetary and non-monetary benefits.

Monetary benefits may include commercial payments and contributions under the applicable benefit-sharing arrangements. Non-monetary benefits may include scientific data, research collaboration, access to samples, and technology-sharing.

The Agreement does not simply abolish patent rights over marine-derived inventions. Rather, it creates obligations concerning the use and benefit-sharing of marine genetic resources that must be considered alongside intellectual property laws.

The precise obligations depend on the Agreement's provisions, implementing arrangements, and whether the relevant State is a Party.

United Nations Treaty Collection+2

5. Patent Conflicts Under International Intellectual Property Law

A. TRIPS Agreement

The TRIPS Agreement establishes international minimum standards for patent protection.

Its important provisions include:

Article 27: Patentable subject matter.

Article 27(2): Certain exclusions based on public order, morality, and environmental considerations.

Article 27(3)(b): Special provisions concerning plants, animals, and microorganisms.

Article 28: Rights conferred on patent owners.

Article 29: Disclosure requirements.

A dispute may arise when a company argues that its deep-sea microorganism invention must receive patent protection, while another State argues that the biological material is a naturally occurring discovery or falls within a permitted exclusion.

TRIPS does not itself establish a comprehensive international ownership system for marine genetic resources.

B. Patent Disclosure and Biological Origin

Patent applications involving deep-sea organisms should provide sufficient technical disclosure to enable a skilled person to reproduce the invention.

Important disclosure questions include:

Where was the organism collected?

What species was identified?

What genetic sequence was isolated?

How was the organism modified?

What technical contribution was made?

What industrial application was developed?

Were the relevant access and benefit-sharing obligations satisfied?

Failure to provide sufficient disclosure may result in objections, refusal, or invalidation under applicable national patent law.

A separate issue is whether the patent application must disclose the source or geographical origin of the biological material. This requirement differs between jurisdictions.

6. Deep-Sea Organism Patent Conflicts Under Indian Law

India has several important legal provisions relevant to deep-sea biological resources and biotechnology patents.

A. Patents Act, 1970

The following provisions are particularly important.

Section 3(c): The mere discovery of a scientific principle or discovery of any living or non-living substance occurring in nature is not an invention.

Section 3(j): Plants and animals, in whole or in part, are excluded from patentability, subject to the statutory exception for microorganisms and other stated exclusions.

Section 3(b): Inventions whose commercial exploitation could seriously prejudice human, animal or plant life, health, or the environment may be excluded.

Section 10(4): Patent specifications must provide the prescribed disclosure of the invention, including how it is performed.

These provisions mean that an applicant cannot obtain a patent simply by discovering a new deep-sea microorganism. However, a qualifying inventive process, engineered microorganism, or biotechnological application may be patentable.

Government of India+1

B. Biological Diversity Act, 2002

The Biological Diversity Act regulates access to biological resources within its scope and addresses benefit-sharing.

The National Biodiversity Authority plays an important regulatory role.

The Biological Diversity (Amendment) Act, 2023 introduced changes to the regulatory framework, including definitions and access-related provisions.

For deep-sea resources, it is necessary to distinguish between:

Resources obtained from India's maritime zones.

Resources obtained from international waters.

Resources obtained from the international seabed Area.

Indian domestic biodiversity legislation and international maritime obligations must be examined according to the geographical origin and circumstances of collection.

C. Patent and Biodiversity Disclosure

India's biotechnology patent examination framework recognises the importance of identifying the source and geographical origin of biological material.

This helps prevent unauthorised exploitation and supports biodiversity-related regulatory compliance.

The patentability examination and biodiversity access approval are related but distinct legal questions.

7. Major Types of Deep-Sea Organism Patent Conflicts

8. Major Challenges in Regulating Deep-Sea Organism Patents

1. Difficulty identifying biological origins

Deep-sea microorganisms may be discovered in remote environments, making it difficult to establish their exact geographical origin.

2. Patent monopolisation

Broad patent claims may restrict scientific research, biotechnology development, and competing commercial applications.

3. Scientific uncertainty

Researchers may not initially understand the biological functions of newly discovered organisms.

4. International jurisdictional conflicts

Different countries may apply different patentability, biodiversity, and disclosure standards.

5. Digital sequence information

Genetic information can be stored, transferred, and commercially used without repeatedly transporting the original biological sample. This creates difficult questions concerning benefit-sharing and intellectual property.

6. Unequal technological capacity

Developing countries may lack the advanced research vessels, laboratories, and sequencing infrastructure needed to participate equally in deep-sea biotechnology.

7. Conservation versus commercialisation

Uncontrolled collection and exploitation may threaten fragile deep-sea ecosystems.

9. Suggestions for Legal and Regulatory Reforms

Several reforms could improve the governance of deep-sea organism patent conflicts:

Establish transparent international databases recording marine genetic resource collections.

Improve disclosure of biological source and geographical origin in patent applications.

Develop clear rules distinguishing natural discoveries from patentable technological inventions.

Strengthen benefit-sharing mechanisms under the BBNJ Agreement.

Promote international cooperation between developed and developing countries.

Establish safeguards against excessively broad biological patent claims.

Improve access to marine genetic research data for public scientific institutions.

Strengthen environmental impact assessments for deep-sea biological collection.

Establish transparent licensing arrangements for commercially valuable marine enzymes and genetic sequences.

Encourage dispute-resolution mechanisms for conflicting patent claims and benefit-sharing obligations.

10. Conclusion

Deep-Sea Organism Patent Conflicts represent an important intersection between biotechnology, intellectual property law, international maritime law, and environmental governance.

The central legal question is how to balance private incentives for scientific innovation against the international community's interest in conserving and fairly benefiting from marine genetic resources.

The judicial principles established in Diamond v. Chakrabarty, Funk Brothers, Myriad Genetics, Netherlands v. European Parliament, and Monsanto v. Cefetra provide important guidance for determining whether biological material or a biotechnology-derived invention qualifies for patent protection.

The entry into force of the BBNJ Agreement on 17 January 2026 has added a significant international framework for marine genetic resources beyond national jurisdiction.

Nevertheless, patent rights and international benefit-sharing obligations remain distinct legal questions. A patent may protect a qualifying technological invention without granting ownership of the naturally occurring organism, the species, or the marine environment from which it originated.

Ultimately, effective regulation requires a balance between scientific innovation, legitimate patent protection, fair benefit-sharing, and conservation of the world's deep-sea biodiversity.

11. Important Case Laws: Quick Revision

Academic research note: These are analogous biotechnology patent precedents, not judgments directly deciding ownership of deep-sea organisms under the BBNJ Agreement. The Butamax–Gevo dispute provides a separate commercial example involving marine-derived genetic technology.

12. Important Legal Sources for Further Study

BBNJ Agreement – United Nations Treaty Collection.

UNCLOS Articles 136–137.

Indian Patents Act – Section 3.

Netherlands v. European Parliament – ECJ judgment.

Myriad Genetics – US Supreme Court judgment.

Monsanto v. Cefetra – ECJ judgment.

Research on marine bioprospecting patents.